Efficacy and safety of cangrelor on top of anticoagulation in patients with myocardial infarction related cardiogenic shock or cardiac arrest receiving va ecmo: preliminary data from a phase 2 trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract Introduction In Out-of-Hospital Cardiac Arrest (OHCA)/Acute Myocardial Infarction– Cardiogenic Shock (AMI-CS) requiring primary PCI and Veno-Arterial ExtraCorporeal Membrane Oxygenation (VA-ECMO), antithrombotic therapy is challenging due to competing thrombotic and bleeding risks and post-OHCA coagulopathy with associated platelet dysfunction. Early clinical data suggest that combination of a individually tailored Cangrelor dosing regimen based on Multiplate test results, combined with background bivalirudin anticoagulation, may be equally effective but safer in terms of bleeding risk than triple therapy (acetylsalicylic acid, P2Y12 inhibitor and anticoagulation) in this setting (1). We designed the SURVIVE phase-2, single-arm prospective clinical trial to assess efficacy and safety of a reduced, adjustable-dose Cangrelor regimen plus Bivalirudin in patients with OHCA and AMI-CS requiring VA-ECMO. Efficacy and safety endpoints were defined as thrombotic and bleeding (BARC ≥3b) adverse events occurring during Cangrelor infusion. Methods We report data from the first 5 consecutive OHCA-AMI-CS patients requiring VA-ECMO and who underwent pPCI treated with reduced, tailored Cangrelor dose (starting dose: 0.125 μg/kg/min without initial bolus) targeting an ADP test value
Fields of Study & Subjects
Antiplatelet Therapy and Cardiovascular Diseases
Mechanical Circulatory Support Devices
Acute Myocardial Infarction Research
Publication details
- Journal / source
- European Heart Journal Supplements
- Volume
- 28
- Issue
- Supplement_3
- Publication date
- 1 March 2026
- Language
- EN